Interstitial Lung Disease Associated with Trastuzumab Deruxtecan in HER2D Metastatic Breast Cancer: a Real-world Experience

被引：0
|
作者：
Shaheen, A. [1 ]
Hayhurst, H. [1 ]
Omokhodion, O. [1 ]
Ayyad, A. [1 ]
机构：
[1] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England
来源：
CLINICAL ONCOLOGY | 2024年 / 36卷 / 04期
关键词：
EMTANSINE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E111 / E112
页数：2
相关论文
共 50 条
  • [31] Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis
    Law, Jeanna Wallenta
    Campbell, Alicyn
    Weller, Colin
    Johanson, Colden
    Broome, Ronda
    Piault, Elisabeth
    Izano, Monika
    Schrag, Andrew
    Tran, Mary
    Brown, Thomas D.
    Kaplan, Henry G.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (03) : 603 - 611
  • [32] Two cases of trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer
    Gocho, Kyoko
    Sato, Kenya
    Iizuka, Noboru
    Sunada, Kouichi
    Nishiya, Shin
    Hamanaka, Nobuyuki
    RESPIROLOGY CASE REPORTS, 2022, 10 (04):
  • [33] Real-world treatment in patients with HER2+metastatic breast cancer
    Colomer, R.
    Hall, P.
    Szkultecka-Debek, M.
    Bondi, R. C.
    Flinois, A.
    Auziere, S.
    Le Cleac'h, J. Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 197 - 205
  • [34] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Schnog, John-John B.
    Samson, Michael J.
    Duits, Ashley J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1143 - 1144
  • [35] Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
    Piezzo, Michela
    D'Aniello, Roberta
    Avallone, Ilaria
    Barba, Bruno
    Cianniello, Daniela
    Cocco, Stefania
    D'Avino, Antonio
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Fusco, Giuseppina
    Piscitelli, Raffaele
    von Arx, Claudia
    De Laurentiis, Michelino
    Maiolino, Piera
    PHARMACEUTICS, 2021, 13 (05)
  • [36] Real-world data of trastuzumab in metastatic cancer
    Vasques, A.
    Baleiras, M.
    Ferreira, A.
    Duarte, T.
    Branco, V.
    Pereira, J.
    Lobo-Martins, S.
    Pinto, M.
    Martins, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S268 - S268
  • [37] Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer
    Dickerson, James
    Moen, Marcus
    Nielsen, Perry
    Tran, Edward
    Suen, Wesley
    Goldhaber-Fiebert, Jeremy D.
    Alarid-Escudero, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
    Sang, Die
    Su, Yanfang
    Zhang, Yurong
    Guan, Yanfeng
    Fan, Shanmin
    Zhang, Jintao
    Zheng, Lijun
    Wang, Yanling
    Guo, Ying
    Lei, Zixuan
    Li, Man
    Yuan, Peng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [39] European real-world experience of patients with HER2+advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: first interim analysis of EUROPA T-DXd
    De laurentiis, Michelino
    Garcia-Saenz, Jose Angel
    Bianchini, Giampaolo
    Saura, Cristina
    Wildiers, Hans
    Allignol, Arthur
    Logue, Amanda
    Lucerna, Markus
    Stamenitis, Sabine
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Trastuzumab deruxtecan for HER2-expressing metastatic colorectal cancer
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07): : S31 - S31
12345